Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annabel Spek

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Urologie (Heidelberg, Germany)|May 4, 2022
[Intravesical gemcitabine for non-muscle invasive bladder cancer]Annabel Spek
Der Urologe. Ausg. A|March 13, 2019
[Chemohormonal therapy for metastatic prostate cancer : Taxane-based approaches]Annabel Spek
Der Urologe. Ausg. A|February 27, 2020
[Nephroureterectomy for upper tract urothelial carcinoma : Effectiveness of single-dose intravesical chemotherapy]Annabel Spek
Urologie (Heidelberg, Germany)|June 28, 2023
[D-mannose for preventing and treating urinary tract infections. A commentary]Annabel Spek
Der Urologe. Ausg. A|April 23, 2021
[Bipolar versus monopolar resection of the prostate for lower urinary tract symptoms caused by benign prostatic obstruction]Annabel Spek
Deutsche Medizinische Wochenschrift (1946)|December 29, 2015
[PSA--recent recommendations of the S3 guideline]Annabel Spek, Christian Stief
Deutsche Medizinische Wochenschrift (1946)|September 25, 2015
[PSA screening]Annabel Spek, Bernadett Szabados, Alexander Roosen, et al.
Systematic Reviews|December 20, 2015
Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance--protocol for a systematic reviewFrank Kunath, Annabel Spek, Katrin Jensen, et al.
International Journal of Clinical Oncology|February 14, 2019
Adjuvant therapy in renal cell carcinoma: the perspective of urologistsAnnabel Spek, B Szabados, J Casuscelli, et al.
Urologic Oncology|July 18, 2017
Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic reviewFriedemann Zengerling, Frank Kunath, Katrin Jensen, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Urologie (Heidelberg, Germany)|May 4, 2022
[Intravesical gemcitabine for non-muscle invasive bladder cancer]Annabel Spek
Der Urologe. Ausg. A|March 13, 2019
[Chemohormonal therapy for metastatic prostate cancer : Taxane-based approaches]Annabel Spek
Der Urologe. Ausg. A|February 27, 2020
[Nephroureterectomy for upper tract urothelial carcinoma : Effectiveness of single-dose intravesical chemotherapy]Annabel Spek
Urologie (Heidelberg, Germany)|June 28, 2023
[D-mannose for preventing and treating urinary tract infections. A commentary]Annabel Spek
Der Urologe. Ausg. A|April 23, 2021
[Bipolar versus monopolar resection of the prostate for lower urinary tract symptoms caused by benign prostatic obstruction]Annabel Spek
Deutsche Medizinische Wochenschrift (1946)|December 29, 2015
[PSA--recent recommendations of the S3 guideline]Annabel Spek, Christian Stief
Deutsche Medizinische Wochenschrift (1946)|September 25, 2015
[PSA screening]Annabel Spek, Bernadett Szabados, Alexander Roosen, et al.
Systematic Reviews|December 20, 2015
Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance--protocol for a systematic reviewFrank Kunath, Annabel Spek, Katrin Jensen, et al.
International Journal of Clinical Oncology|February 14, 2019
Adjuvant therapy in renal cell carcinoma: the perspective of urologistsAnnabel Spek, B Szabados, J Casuscelli, et al.
Urologic Oncology|July 18, 2017
Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic reviewFriedemann Zengerling, Frank Kunath, Katrin Jensen, et al.
Pageof 3